Neuroscience
Neurotransmitter receptors function via various G-protein coupled and G-protein independent mechanisms that activate downstream intracellular signaling pathways such as cAMP/PKA, PI3K/AKT, phospholipase A2, and phospholipase C pathways. For instance, dopamine receptors act through adenylate cyclase to activate PKA and other signaling molecules, thereby mediate gene expression through the actions of CREB and other transcription factors. Other neurotransmitters such as NMDAR or AMPAR are associated with ion channels that control flux of Ca2+ and Na+, thus propagating the action potential across the post-synaptic neuron.
Dysfunctions in GABAergic/glutamatergic/serotonergic/dopaminergic pathways result in a broad range of neurological disorders such as chronic pain, neurodegenerative diseases, and insomnia, as well as mental disorders including schizophrenia, bipolar disorder, depression, and addiction.
-
B7200 (+)-Tubocurarine chlorideSummary: nicotinic acetylcholine receptor antagonist
-
B6990 DMAB-anabaseine dihydrochlorideSummary: α7-containing neuronal nicotinic receptor partial agonist
-
B7007 PNU 282987Summary: α7 nAChR agonist
-
B7030 Dihydro-β-erythroidine hydrobromideSummary: antagonist of nAChRs
-
B7053 TMPH hydrochlorideSummary: neuronal nicotinic ACh receptors (nAChRs) antagonist
-
B7089 TC 1698 dihydrochlorideSummary: nicotinic α7 receptor agonist
-
B7168 TC 2559 difumarateSummary: partial agonist of α4β2 nicotinic acetylcholine receptor
-
B7205 Mecamylamine hydrochlorideSummary: nicotinic acetylcholine receptor antagonist
-
B7243 NS 1738Summary: positive allosteric modulator of α7 nicotinic acetylcholine receptor
-
B7282 PHA 568487Summary: α7 nicotinic acetylcholine receptor agonist